Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND)

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015).
  Medline CASGoogle Scholar
• 2. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403–2413 (1997). • Provides first relevant insights on the management of advanced pancreatic cancer. Results on a randomized trial performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer have been reported.
  Medline CASGoogle Scholar
• 3. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J. Clin. Oncol. 20, 3270–3275 (2002).
  Medline CASGoogle Scholar
• 4. Scheithauer W, Schüll B, Ulrich-Pur H et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann. Oncol. 14, 97–104 (2003).
  Medline CASGoogle Scholar
• 5. Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22, 3776–3783 (2004).
  MedlineGoogle Scholar
• 6. Oettle H, Richards D, Ramanathan RK et al. A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 16, 1639–1645 (2005).
  Medline CASGoogle Scholar
• 7. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23, 3509–3516 (2005).
  Medline CASGoogle Scholar
• 8. Abou-Alfa GK, Letourneau R, Harker G et al. Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. 24, 4441–4447 (2006).
  Medline CASGoogle Scholar
• 9. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).
  Medline CASGoogle Scholar
• 10. Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946–3952 (2006).
  Medline CASGoogle Scholar
• 11. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
  Medline CASGoogle Scholar
• 12. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
  Medline CASGoogle Scholar
• 13. Wang-Gillam A, Dean A, Shan YS et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase III trial. Lancet 387, 545–557 (2016).
  Medline CASGoogle Scholar
• 14. Oettle H, Riess H, Stieler JM et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J. Clin. Oncol. 32, 2423–2429 (2014).
  Medline CASGoogle Scholar
• 15. Buchler P, Reber HA, Ullrich A et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 134, 772–782 (2003).
  MedlineGoogle Scholar
• 16. Itakura J, Ishiwata T, Shen B et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 85, 27–34 (2000).
  Medline CASGoogle Scholar
• 17. Masood R, Cai J, Zheng T et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98, 1904–1913 (2001).
  Medline CASGoogle Scholar
• 18. Von Marschall Z, Cramer T, Hocker M et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119, 358–1372 (2000).
  MedlineGoogle Scholar
• 19. Solorzano CC, Baker CH, Bruns CJ et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. 16, 359–370 (2001).
  Medline CASGoogle Scholar
• 20. Itakura J, Ishiwata T, Friess H et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 3, 1309–1316 (1997).
  Medline CASGoogle Scholar
• 21. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231–2237 (2009).
  Medline CASGoogle Scholar
• 22. Javle M, Yu J, Garrett C et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a Phase II study. Br. J. Cancer 100, 1842–1845 (2009).
  Medline CASGoogle Scholar
• 23. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617–3622 (2010).
  Medline CASGoogle Scholar
• 24. Kindler HL, Ioka T, Richel DJ et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised Phase III study. Lancet Oncol. 12, 256–262 (2011).
  Medline CASGoogle Scholar
• 25. Gonçalves A, Gilabert M, Francois E et al. BAYPAN study: a double-blind Phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann. Oncol. 23, 2799–2805 (2012).
  Medline CASGoogle Scholar
• 26. Bergmann LK, Maute L, Heil G et al. A prospective randomized Phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Eur. J. Cancer 51, 27–36 (2015).
  Medline CASGoogle Scholar
• 27. Cascinu S, Berardi L, Sobrero A et al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized Phase II study. Dig. Liver Dis. 46, 182–186 (2014).
  Medline CASGoogle Scholar
• 28. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245–255 (2011).
  Medline CASGoogle Scholar
• 29. Wu RY, Kong PF, Xia LP et al. Regorafenib promotes antitumor immunity via inhibiting PDL-1 and IDO1 expression in melanoma. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-18-2840 (2019) (Epub ahead of print).
  Google Scholar
• 30. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet 381, 303–312 (2013). •• Reports data on efficacy and toxicity of regorafenib in patients with previously treated metastatic colorectal cancer, which are relevant for the marketing authorization of regorafenib in metastatic colorectal cancer.
  Medline CASGoogle Scholar
• 31. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet 381, 295–302 (2013). •• Reports data on efficacy and toxicity of regorafenib in patients with gastrointestinal tumors, which are relevant for the marketing authorization of regorafenib in patients with gastrointestinal tumors.
  Medline CASGoogle Scholar
• 32. Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 389, 56–66 (2017). •• Reports data on efficacy and toxicity of regorafenib in patients with hepatocellular carcinoma used for marketing authorization of regorafenib in this setting.
  Medline CASGoogle Scholar
• 33. Lombardi G, De Salvo GL, Brandes AA et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, Phase II trial. Lancet Oncol. 20(1), 110–119 (2019).
  Medline CASGoogle Scholar
• 34. Duffaud F, Mir O, Boudou-Rouquette P et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, Phase II study. Lancet Oncol. 20(1), 120–133 (2019).
  Medline CASGoogle Scholar
• 35. Demols A, Borbath I, Van Den Eynde M et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: a randomized double-blinded Phase II trial – the REACHIN trial. J. Clin. Oncol. 37(Suppl.4), 345 Abstract (2019).
  Google Scholar
• 36. Fukuoka S, Hara H, Takahashi N et al. Regorafenib plus nivolumab in patients with advanced gastric cancer (GC) or colorectal cancer (CRC): an open-label, dose-finding and dose-expansion Phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 37(Suppl. 15), 2522–2522 (2019).
  Google Scholar
• 37. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1. 1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 38. Mayer B, Karakhanova S, Bauer N et al. A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 390(11), 1125–1134 (2017).
  Medline CASGoogle Scholar
• 39. Bush KT, Boichard A, Tsigelny IF. In vitro elucidation of drug combination synergy in treatment of pancreatic ductal adenocarcinoma. Anticancer Res. 38(4), 1967–1977 (2018).
  Medline CASGoogle Scholar
• 40. Salmon JS, Hwang JJ, Robinson MM et al. Phase II study of regorafenib (Reg) in patients with previously treated advanced pancreatic cancer (APC). J. Clin. Oncol. 35(Suppl.), e15751 Abstract (2017).
  Google Scholar